Get started
Author

Angelo Ruggiero

Observed names: A RUGGIERO, A Ruggiero, A. Ruggiero, Angelo RUGGIERO, Ruggiero, Ruggiero Angelo, Ruggiero, Angelo
Institution: Hospital Del Mar
ORCID: 0000-0002-4658-7391
Observed ORCID: 0000-0002-4658-7391
OpenAlex ID: A5025725407
Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
2021 · A. Ruggiero, G. Fabbrocini, et al. · Clinical and Experimental Dermatology · 100
PDF
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
2022 · Matteo Megna, Nello Tommasino, et al. · Journal of Dermatological Treatment · 91
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
2022 · Angelo Ruggiero, Vincenzo Picone, et al. · Clinical Cosmetic and Investigational Dermatology · 90
PDF
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose
2021 · A. Villani, G. Fabbrocini, et al. · Journal of the European Academy of Dermatology and Venereology · 85
MRI in Pregnancy and Precision Medicine: A Review from Literature
2021 · Gianluca Gatta, Graziella Di Grezia, et al. · Journal of Personalized Medicine · 72
PDF
Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients
1995 · Tortora, Ciardiello, et al. · PubMed · 70
Teledermatology for acne during COVID‐19: high patients’ satisfaction in spite of the emergency
2020 · A. Ruggiero, M. Megna, et al. · Journal of the European Academy of Dermatology and Venereology · 65
PDF
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
2023 · Fabrizio Martora, Massimiliano Scalvenzi, et al. · Medicina · 60
PDF
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
2022 · Matteo Megna, Luca Potestio, et al. · Dermatologic Therapy · 60
PDF
New frontiers in personalized medicine in psoriasis
2022 · Elisa Camela, Luca Potestio, et al. · Expert Opinion on Biological Therapy · 59
PDF
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
2022 · Matteo Megna, Luca Potestio, et al. · Journal of Dermatological Treatment · 58
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data of a real‐life 16‐week retrospective study
2020 · Matteo Megna, Gabriella Fabbrocini, et al. · Dermatologic Therapy · 58
PDF
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis
2023 · Maddalena Napolitano, Francesca di Vico, et al. · Frontiers in Medicine · 57
PDF
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review
2022 · Angelo Ruggiero, Fabrizio Martora, et al. · Biomedicines · 57
PDF
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients
2023 · Matteo Megna, Elisa Camela, et al. · Expert Opinion on Drug Safety · 53
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study
2020 · Angelo Ruggiero, Gabriella Fabbrocini, et al. · Dermatologic Therapy · 53
PDF
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
2021 · Angelo Ruggiero, Gabriella Fabbrocini, et al. · Dermatologic Therapy · 52
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period
2021 · Matteo Megna, Eleonora Cinelli, et al. · Archives of Dermatological Research · 52
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
2022 · Matteo Megna, Luca Potestio, et al. · Dermatologic Therapy · 50
PDF
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
2022 · Angelo Ruggiero, Fabrizio Martora, et al. · Clinical Cosmetic and Investigational Dermatology · 48
PDF
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
2022 · Angelo Ruggiero, Luca Potestio, et al. · Psoriasis Targets and Therapy · 48
PDF
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
2020 · Matteo Megna, Gabriella Fabbrocini, et al. · Journal of Dermatological Treatment · 48
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears
2020 · Matteo Megna, Angelo Ruggiero, et al. · Journal of Dermatological Treatment · 47
Towards Personalized Medicine in Psoriasis: Current Progress
2022 · Elisa Camela, Luca Potestio, et al. · Psoriasis Targets and Therapy · 46
PDF
Reply to “Psoriasis exacerbation after COVID‐19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al.
2021 · M. Megna, L. Potestio, et al. · Journal of the European Academy of Dermatology and Venereology · 46
PDF
Works count: 163
Citation count: 3,392
H-index: 38
I10-index: 89
Year
Topic
Type